CD4 and diabetes mellitus: This interpretation is further supported by our observation that, in contrast to anti-CD4 mAb, anti-CD8 and anti-CD3 mAb (44) administration into DT-treated NOD.DEREG mice interfered with the progression to overt diabetes (Figure 3F), despite substantial histopathological changes (Figure 3E).